Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 3/20 | 0.56 |
| ▸ | PPARG | P37231 | 15/20 | 0.42 |
| ▸ | PPARA | Q07869 | 6/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3000561 | 0.91 | PTGES (0.55) | PTGESPPARGPPARA | |
| SCHEMBL3002045 | 0.84 | PTGES (0.59) | PTGESPPARGPPARA | |
| Hydrochloric Acid SCHEMBL3011495 | 0.84 | PTGES (0.41) | PTGESPPARGPPARAHTR6 | |
| Hydrochloric Acid SCHEMBL333805 | 0.82 | PTGES (0.55) | PTGESPPARGPPARASERPINE1 | |
| Hydrochloric Acid SCHEMBL334147 | 0.82 | PTGES (0.51) | PTGESPPARGPPARASERPINE1 | |
| Hydrochloric Acid SCHEMBL333803 | 0.82 | PTGES (0.57) | PTGESPPARGPPARA | |
| SCHEMBL4027503 | 0.82 | PTGES (0.71) | PTGESPPARGPPARASERPINE1 | |
| SCHEMBL3000522 | 0.81 | PTGES (0.48) | PTGES | |
| SCHEMBL3013332 | 0.81 | PTGES (0.56) | PTGESPPARGPPARA | |
| Hydrochloric Acid SCHEMBL3007565 | 0.81 | PTGES (0.55) | PTGESPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814857-B1 | ISOTOPICALLY MARKED QUINOLINE DERIVATIVES AS ADENOSIN A3 RECEPTOR LIGANDS | SANOFI AVENTIS (FR) | 2010-09-01 | — | — | EP | claimed |
| US-20100197687-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197687-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, TPH1 | PTGES 33/4885PPARG 2505/4885PPARA 3519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.